HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT02019329

A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone

This study evaluated the safety of RO5545965 for people with schizophrenia.

Medication studyAges 18–60United States
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety of RO5545965 for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Listed locations
GlendaleSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study clarity

Study information

Study start dateJanuary 2014
Recruitment status
Completed
Enrollment listed in the registry
32
Sponsor
Hoffmann-La Roche
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug, OTHER
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 60 Years
Official registry ID
NCT02019329
Official title
Show the full official title

A SINGLE-CENTER, RANDOMIZED, INVESTIGATOR/SUBJECT-BLIND, MULTIPLE-DOSE, PLACEBO-CONTROLLED, PARALLEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO5545965 IN PATIENTS WITH SCHIZOPHRENIA ON RISPERIDONE.

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Glendale

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety of RO5545965 for people with schizophrenia.

Who is behind this study?

The study sponsor is Hoffmann-La Roche.

Did this study involve medication?

Yes. The study involved medication, including RO5545965 and risperidone.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies